Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03861936 · ClinicalTrials.gov registry record · Phase 2
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
A Phase 2 study of Masseter Muscle Prominence, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 14
- Study locations
NCT03861936 is a Phase 2 study of Masseter Muscle Prominence that has completed, run by Allergan. The registered enrollment target is 150 participants. The trial reports 14 study locations across 10 states.
The verdict
NCT03861936, a Phase 2 study of Masseter Muscle Prominence, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 14
- Study locations
Study Summary
Based on the results of the Phase 2 Study 191622-130 \[NCT02010775\], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
Conditions Studied
Interventions
- DRUG Normal saline
- BIOLOGICAL OnabotulinumtoxinA
Study Locations (14)
California
- Westside Aesthetics - Los Angeles
- Skin Care and Laser Physicians of Beverly Hills - Los Angeles
- Cosmetic Laser Dermatology - San Diego
Texas
- DermResearch, Inc. - Austin
- Bellaire Dermatology Associates - Bellaire
- Austin Institute for Clinical Research, Inc. - Pflugerville
Alabama
- Total Skin & Beauty Dermatology Center, PC - Birmingham
Florida
- Baumann Cosmetic and Research Institute - Miami
Illinois
- DeNova Research - Chicago
Louisiana
- Etre, Cosmetic Dermatology and Laser Center - New Orleans
Missouri
- Saint Louis University Dermatology - St Louis
Nebraska
- Skin Specialists, PC - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2020-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03861936
The ClinicalTrials.gov registry entry for NCT03861936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Masseter Muscle Prominence appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT03861936 reports 14 study locations spanning 10 distinct geographic areas - top geographies include California, Texas, Alabama.
Frequently Asked Questions
What is clinical trial NCT03861936 about?
NCT03861936 is a clinical study titled "BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence". Based on the results of the Phase 2 Study 191622-130 \[NCT02010775\], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
What is the current status of trial NCT03861936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2019-05-16. Estimated completion is 2020-07-02.
What conditions does trial NCT03861936 study?
This clinical trial studies the following conditions: Masseter Muscle Prominence.
What interventions are being tested in trial NCT03861936?
The interventions under investigation include: Normal saline (DRUG), OnabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT03861936?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03861936 being conducted?
This trial has 14 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.